LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT01209650
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use.
Named Patient Use (NPU)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie BIBW 2992's efficacy in erlotinib/gefitinib-resistant NSCLC?
How does BIBW 2992 compare to other EGFR tyrosine kinase inhibitors in last-line NSCLC treatment?
Which biomarkers correlate with response to BIBW 2992 in advanced non-small cell lung cancer patients?
What are the most common adverse events reported in BIBW 2992 compassionate use programs for NSCLC?
What combination therapies involving BIBW 2992 are being explored for EGFR-mutated NSCLC by Boehringer Ingelheim?
Trial Locations
- Locations (1)
1200.47.1 Boehringer Ingelheim Investigational Site
🇦🇺North Ryde, New South Wales, Australia